Hyloris Pharmaceuticals SA (52U) Stock Statistics & Valuation Metrics

Hyloris Pharmaceuticals SA has a market cap or net worth of €138.60M. The enterprise value is €165.61M.

Hyloris Pharmaceuticals SA has 28,000,374 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hyloris Pharmaceuticals SA’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -30.83%.

The current PE Ratio of Hyloris Pharmaceuticals SA is ―. Hyloris Pharmaceuticals SA’s PEG ratio is ―.

In the last 12 months, Hyloris Pharmaceuticals SA had revenue of 7.21M and earned -6.33M in profits. Earnings per share was -0.23.

In the last 12 months, operating cash flow was -6.69M and capital expenditures -7.00K, giving a free cash flow of -6.70M billion.

Hyloris Pharmaceuticals SA pays an annual dividend of ―, resulting in a dividend yield of ―

Hyloris Pharmaceuticals SA upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).

Hyloris Pharmaceuticals SA as a current ratio of 3.89, with Debt / Equity ratio of 5.71%

In the past 12 months, Hyloris Pharmaceuticals SA has paid -374.00K in taxes.

Hyloris Pharmaceuticals SA EV to EBITDA ratio is -20.95, with an EV/FCF ratio of -26.71.

Hyloris Pharmaceuticals SA has €19.12M in cash and marketable securities with €1.81M in debt, giving a net cash position of €17.47M billion.

Gross margin is 96.90%, with operating margin of -129.53%, and net profit margin of -87.89%.

The average price target for Hyloris Pharmaceuticals SA is €14.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy